Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.5735
0.00 (0.00%)
At close: Jun 26, 2026, 4:00 PM EDT
0.5453
-0.0282 (-4.92%)
After-hours: Jun 26, 2026, 7:20 PM EDT
Galmed Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
3.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGLMD News
- 5 days ago - Galmed announces restructured acquisition terms for Colospan - TheFly
- 5 days ago - Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd. - PRNewsWire
- 19 days ago - Galmed to acquire Colospan in cash and stock deal - TheFly
- 19 days ago - Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - PRNewsWire
- 25 days ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 25 days ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 25 days ago - Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PRNewsWire
- 6 weeks ago - Galmed reports results from first-in-man PK study of Aramchol Meglumine - TheFly